As of September 30, 2023, Neumora had $519.5 million in cash, cash equivalents and marketable securities. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2023, will enable it to fund its operating plan into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NMRA:
- Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Neumora Therapeutics to Participate in Upcoming Conferences in November
- Neumora initiated with Outperform, $26 fair value at William Blair
- Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
- Neumora Therapeutics appoints Lenz as EVP, Head of Research, Development
